Search Videos and More
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: SABCS 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at SABCS 2025 in San Antonio, Texas providing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data mean, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.
News
Seeing Is Believing
How Technicolor Images of Tumor Samples Are Changing Cancer Research
News
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
The SWI/SNF Ig-Fold for Transcription Factor Interactions or ‘SWIFT’ domain on mSWI/SNF chromatin remodeling complexes engage proteins called transcription factors (TFs) to target specialized genes along human DNA—often cancer-promoting genes—flagging SWIFT-TF interactions as promising new therapeutic targets.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
Video
Omar Nadeem, MD discusses results of the Phase II d-PRISM study
Daratumumab in high-rish MGUS and low-risk smoldering myeloma
Video
Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study
Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning
Video
Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia
Video
Austin Kim, MD discusses phase I/II study
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Video
Jennifer Brown, MD, PhD discusses results form the ALPINE trial
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)